Detalhe da pesquisa
1.
Essential thrombocythemia: challenges in clinical practice and future prospects.
Blood
; 141(16): 1943-1953, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36379024
2.
Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives.
Cancer
; 2024 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38373144
3.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet
; 401(10373): 269-280, 2023 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709073
4.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood
; 139(19): 2931-2941, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007321
5.
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268448
6.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Value Health
; 27(5): 607-613, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311180
7.
How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond.
Br J Haematol
; 197(4): 407-416, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35191542
8.
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Br J Haematol
; 198(2): 317-327, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35476316
9.
Current and future status of JAK inhibitors.
Lancet
; 398(10302): 803-816, 2021 08 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34454676
10.
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Haematologica
; 107(7): 1599-1607, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551507
11.
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
Future Oncol
; 18(22): 2393-2402, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35510486
12.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Future Oncol
; 18(27): 2987-2997, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950489
13.
Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre.
Br J Haematol
; 193(4): 792-797, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33751548
14.
Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms.
Br J Haematol
; 193(1): 150-154, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33159465
15.
Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
N Engl J Med
; 379(15): 1416-1430, 2018 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30304655
16.
How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
Br J Haematol
; 189(4): 625-634, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32150650
17.
Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms.
Br J Haematol
; 191(1): 21-36, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32167592
18.
Management of myelofibrosis after ruxolitinib failure.
Ann Hematol
; 99(6): 1177-1191, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32198525
19.
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Am J Hematol
; 95(6): 594-603, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32129512
20.
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.
Am J Hematol
; 95(2): 156-166, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31721282